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Summary
The B lymphoproliferative disorders B chronic lymphocytic leukemia (B-CLL) and hairy cell
leukemia (HCL) produce a number ofautocrine growth factors, including tumor necrosis factor
(TNF), interleukin 6 (IL6), and IL1, all of which may induce positive feedback growth loops.
If such malignancies depend on these autocrine growth loops for survival, their interruption
may be therapeutically valuable. Interferon a (IFN-cx) abrogates TNF- or IL-6-induced proliferation
of HCL and B-CLL cells in vitro and has therapeutic activity in these diseases. We have investigated
the possibility that IFN-ci may act by interrupting autocrine growth factor loops. If purified
B-CLL or HCL cells are cultured in the presence of TNF, there is induction of mRNA for
TNF, IL Act, 1110, and IL-6. However, culture in the presence of IFN-ci in addition to TNF
reduced the level of mRNA for all these cytokines, compared with cells cultured in TNF alone.
While cytokine mRNA levels were diminished, levels of mRNA for the ribonuclease activator
2-5A synthetase were increased. Analysis of the kinetics of cytokine mRNA production showed
that levels fall shortly after the rise of 2-5A synthetase mRNA. IFN-01 may produce these effects
by shortening the half-life of cytokine mRNA, since TNF mRNA half-life in B-CLL and HCL
cells is substantially reduced when the cells are cultured with IFN-tac. These data suggest that
ON-a may mediate its therapeutic effects in these malignancies by blocking autocrine growth
factor loops.
A
utocrine production of growth factors to which a malig-
nant cell expresses receptors has long been a postulated
mechanism for tumor growth (1) and has recently been shown
to occur in several hematological malignancies. Acute my-
eloid leukemia blast cells produce granulocyte/macrophage
CSF and express receptors for this cytokine, which promotes
clonogenic growth (2). Chronic malignancies of B cellscon-
sistently show evidence of autocrine growth, since the neo-
plastic cells of multiple myeloma (3) produce IL6, while B
chronic lymphocytic leukemia (B-CLL)t and hairy cell leu-
kemia (HCL) produce and respond to a variety of cytokines,
including IL A (4, 5), IL6 (6, 7), and TNF (8, 9). Levels of
constitutive cytokine production are variable (6, 7, 10), but
induction of high levels can be attained after exposure to
cytokine proteins (8) .
If these malignancies are dependent on autocrine growth
factors for survival, interruption of the autocrine loop would
be of therapeutic value. TNF promotes viability of cells ob-
1 Abbreviations used in this paper B-CLL, B chronic lymphocytic leukemia;
HCL, hairy cell leukemia.
tained from patients with HCL or B-CLL (8) and also in-
duces these malignant B cells into cell cycle so that culture
with TNF protein induces expression of mRNA for c-myc,
coo, and cjun (11). TNF also promotes increased thymidine
incorporation (8, 12). We have previously shown that IFN-01
almost completely abrogates TNF-induced enhancement of
thymidine uptake in cells from patients with B-CLL and HCL,
while IFN-y has no significant effect (8). IFN-ot has been
shown to have therapeutic activity in HCL and B-CLL in
vivo (13, 14), and we now show that IFN-ci may exert this
therapeutic effect by reducing expression of mRNA for au-
tocrine growth-promoting cytokines in these malignant cells.
Materials and Methods
PatientDetails.
￿
12 patients with B lymphoproliferative disorders
(eight with BCLL, three with BCLL/PL, and one with HCL)
were studied on 18 occasions in various partsof this study. Clinical
data and diagnosis (FAB classification) (15) are shown in Table 1.
Cytokines. rTNF (sp act, 6.63 x 106 U/mg) was a gift of
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U/mg) was a gift of Kirby Warrick, Slough, UK.
Probes. The TNF probe (an 800-bp EcoRI fragment) was
provided by Dr. M. Shepard, Genentech Inc., San Francisco, CA.
The11,10probe wasa530-bp BamHI-NdeI fragment, and the11,1x
probe was a 460-bp EcoRI-BamHI fragment, both provided by
Dr. P. Lomedico, Hoffman-La Roche, Inc., Nutley, NJ. The IIr6
probe was a 517-bp EcoRI-HindIII fragment provided by Dr. E.
Kawashima, GlaxoIMB, Geneva, andthe7B6 probe was a 708-bp
Pstl-DraII fragment provided by Prof. U. Torelli, University of
Modena, Modena, Italy. The tubulin probewas a 1.4-kbPstl frag-
ment provided by Dr. K. Philpott, Clinical Research Centre,
Harrow, UK. The B-actin probe, a 2-kb HindlII fragment, was
provided by Dr. S. Katzav, St. Jude Childrens Research Hospital,
Memphis, TN, and the 2-SA synthetose probe was provided by
Dr. K. Goneshoguru, Royal Free Hospital, London, UK.
Lymphocyte Separation.
￿
Venous blood taken into preservative-
free heparin was layered onto lymphoprep (Nyegaard, Oslo, Nor-
way), and the mononuclear cellsin the interface were depleted of
monocytes by adherence to plastic for 90 min at 37°C. The popu-
lation was then depleted ofTcellsby double E-rosetting.Thecom-
position of the resulting PBL population was assessed by im-
munophenotyping, and contained <0.5% CD3' T cells or
CD14' monocytes and (in patients 2-12) >98% CD5' B-CLL
cells (Table 1). All cell preparation and culture was undertaken in
RPMI 1640 (Gibco Laboratories, Uxbridge, UK) supplemented
with 2 mM glutamine (Gibco Laboratories) and 100 IU/ml strep-
tomycin/penicillin (Gibco Laboratories)in thepresence of 10% FCS
(Sera-Lab, Crawley, Sussex, UK). Cells were cultured in medium
containing 250U/ml TNFor 250U/ml TNFand500U/ml IFN-(X,
and were harvested at various time points for RNA extraction.
Thedosesofcytokineschosenwere thoseat whichoptimumeffect
had been demonstrated in thymidine incorporation assays (8).
Phenotyping.
￿
Phenotyping was performedby indirect immuno-
fluorescence usingamicroplate method (16). OKT3 (CD3; Ortho
Diagnostic Systems, Inc., Westwood, MA), RFT1 (CD5, a gift
Table 1 .
￿
Patient Details
Immunophenotype was determined pre-depletion of monocytes and T cells.
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ofProfessorG. Janossy, Immunology Department, RoyalFree Hos-
pital), and Leu-M3 (CD14; Becton Dickinson & Co., Mountain
View, CA) were used as first layer mAb, while fluorescein- or
rhodamine-conjugatedgoat anti-mouse Ig (Southern Biotechnology
Associates, Birmingham, AL) was used for the second layer. 500
cells were analyzed using an immunofluorescent microscope. All
purified B-CLL preparations contained >98% CD5' B cells,
while >98% of HCL patient Tdepleted lymphocytes had mor-
phological andtartrate-resistant acid phosphotase staining charac-
teristics of HCL cells.
mRNA Extraction.
￿
Cytoplasmic RNAwasextractedfrom PBLs
using the detergent lysis method (17). Briefly, cells were washed
in PBS and resuspended in hypotonicbuffer (10mM Tris HCI, pH
7.8, 150 mM NaCl)containing 10 mM vanadylribonuclease com-
plex (Bethesda Research Laboratories, Gaithersburg,MD) and1%
NP-40 (Shell Chemicals). The nuclei were pelleted by centrifuga-
tion, and the cytoplasmic extract was treated with 1% SDS, fol-
lowed by phenol chloroform extraction andsalt ethanolprecipita-
tion. RNA was quantified and either size fractionated on a 1%
agarose/formaldehyde geland transferred overnight to nitrocellu-
lose or applied directly to nitrocellulose via a slot blot apparatus
(Schleicher and Schuell, Inc.).
Filters were baked for 2 h at 80°C and then prehybridized in
50% formamide, 5x SSC, 5x Denhardt's solution, and 50 Fcg/ml
denatured salmon sperm DNA at 42'C for 4-8 h. cDNA probes
were labeled by random oligopriming using ['2P]dCTP (Amer-
sham International, Amersham, UK), and hybridization was car-
ried out for 16 h at 42°C. Filters were washed twice in 2x
SSC/0.1% SDS, at room temperature and twicein 0.2x SSC/0.1%
SDS at 65°C, and exposed to Fuji RX film for 1-7 d at -70°C
with intensifying screens. Autoradiograms were scanned using a
chromoscan (LKB Instruments, Inc., Gaithersburg, MD). Integrals
obtained from the linear phase of the film were normalized with
respect to the control probe.
Actinom,win D mRNA Ha-Life Studies.
￿
Cultures ofcellsat 2 x
106/ml in RPMI 1640 and 10% FCS were set up in the presence
No. Age/sex WBC Treatment
x 10-'
1 62/F 55 Nil
2 74/M 164 Nil
3 82/M 73 Nil
4 68/M 92 Nil
5 66/M 274 Nil
6 77/F 34 Nil
7 67/F 105 Nil
8 64/17 114 Nil
9 82/M 233 Nil
10 67/M 70 Nil
11 64/M 88 Chlorambucil
12 42/M 120 Nil
Diagnosis Ig CD5
Immunophenotype
(percent positive)
CD2 CD19
HCL IgGK 9 10 77
B-CLL/PL IgMK 95 15 76
B-CLL IgMK 98 10 80
B-CLL/PL IgMX 95 2 93
B-CLL IgMK 97 2 92
B-CLL/PL IgMx 97 1 82
B-CLL IgMK 97 4 91
B-CLL IgMK 98 4 88
B-CLL IgMK 97 2 95
B-CLL IgMK 97 3 84
B-CLL IgMK 93 4 81
B-CLL IgMK 97 2 79Results
Time in Hours
Figure 1 .
￿
Detailed time courses of accumulation ofmRNA for the au-
tocrine growth factor TNF in one patient with HCL (A), two patients
with B-CLL (B and C) and one patient with B-CLL/PL (D)whose cells
were cultured in the presence ofTNF or TNF and IFN-a, as described
in Materials and Methods. Cytoplasmic RNA was extracted at various
time intervals and applied to nitrocellulose filters in doubling dilutions.
The filter was reprobed with the constitutively expressed protein 7116 to
confirm equal loading, and cytokinemRNA is expressed relative to 7116
mRNA .
of 250 U/ml TNF or 250 U/ml TNF and 500 U/ml IFN-a (see
Results) . After 24 h of incubation, transcription was blocked by
adding actinomycinD to culture medium at a final concentration
of 5 F,g/ml . RNA was extracted from these treated cells 30-360
min later.
Downregulation ofCytokine mRNA byIFN-a .
￿
Fresh cells
obtained from patients withB lymphoproliferative disorders
contain variable levels ofmRNA for the growth factorsTNF
(10), IL6 (6, 7), and IL1 (5) . Levels of cytokine mRNA can
be increased by culture in the presence of the growth factor
proteins themselves, which thereby accelerate the onset of
autocrine growth when the cells are studied ex vivo (8). To
determine the effects of IFN-a on this positive feedback
2 .5
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Figure 3 .
￿
Effect of IFN-a on
TNF, IIr1a, IL10, and IL6
mRNA, accumulating at 24 h
with and without IFN-a . Data
shown are from all patients exam-
ined in this part of the study (n
= 5) . For each cytokine, bars rep-
resent themean percent ± SD of
cytokinemRNA in the presence
TNFandIFN-a, comparedwith
that in the presence ofTNF alone. Paired t test shows highly significant
effect for IFN-a on all cytokine mRNA levels (p < 0.01) .
growth loop, we stimulated CLL andHCL cells with TNF,
and measured the effect ofIFN-a on steady-state cytokine
mRNA concentrations. Fig. 1 shows detailed time courses
of TNFmRNA expression in one patient with HCL (A),
two patients with B-CLL (B and C), and one patient with
BCLLPL (D) . In the presence of exogenous TNF protein
alone, TNF mRNA levels rose above constitutive levels and
peaked by 24-40 h . However, cultureof cells in thepresence
of both TNF and IFN-oz substantially abrogated this rise in
cytokine message. IFN-a has asimilar effect on the accumu-
lation ofmRNA for three other cytokines, IL -6 (Fig. 2 a),
and IL1a and 11710 (Fig. 2 b) . Fig . 3 summarizes these data
for all patients examined in this part of the study and illus-
trates cytokine mRNA at 24 h of culture in the presence of
both TNF and IFN-a or TNF alone. The data show consis-
tent reduction in cytokine mRNA levels in the presence of
IFN-a.
Mechanism by which IFN-a DownregulatesmRNA .
￿
Sup-
pression of cytokinemRNA accumulation did not represent
aglobal effect on cellular steady-state accumulation ofmRNA :
levels ofmRNA for structural proteins such as tubulin were
unaffected by IFN-a. Moreover, levels of mRNA encoding
the enzyme 2-5A synthetase substantially increased after cul-
ture with IFN-a (Fig . 4) . 2-5A synthetase is a potent in-
ducer of ribonucleases (18), which in turn increase degrada-
tion of certain mRNA species. We determined if increased
degradation was indeed the mechanismby which IFN-a re-
duced steady-state cytokinemRNA . FreshmRNA transcrip-
tion was inhibited with actinomycin D, allowing measure-
ment of the half-life of cytokine mRNA . Cytokine mRNA
is short lived in these malignant B cells compared with the
- ILia
IL1a+aIFN
￿
Figure 2 .
￿
Detailed time course of ac-
IL 1p
￿
cumulation ofmRNA for the autocrine
IL1f+aIFN
￿
growth factors IL6 (a), and rIIAct and
ILlO (b) in representative B-CLL patients
whose cells were culturedin the presence
ofTNF orTNFand IFN-a, as described
Material and Methods. Cytoplasmic
RNA was extracted at intervals and ap-
plied to nitrocellulose filters in doubling
dilutions. The filter was reprobed with
the constitutively expressed protein7B6
to confirm equal loading, and cytokine
mRNA is expressed relative to 7116
mRNA .
A
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TNF"aIFN
24 4s 72mRNA for structural proteins, illustrated in Fig . 5a forTNF
andtubulin, respectively. However, Fig . 5 b showsthatTNF
mRNA half-life is further reduced by 33-50% in the pres-
ence of IFN-a .
Discussion
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Figure 4.
￿
Induction of 2-5A synthetase mRNA by
IFN-a . Purified B cells from HCl or B-CLL patients were
cultured in medium alone or with IFN-a for 18 h .
Northern blots from four representativepatients are shown
here . Pre-culture (lanes 1, 3, S, and 7), and an absence
of or low levels of mRNA for 2-5A synthetase were
present ; after culture with IFN-a (lanes 2, 4, 6, and 8),
there was induction ofmRNA for 2-5A synthetase.
This study investigated one mechanism by which IFN-ac
may exert its therapeutic activity in B-CLL andHCL. The
results of the current study show that IFN-ct can interrupt
Figure 5 .
￿
Effect of IFN-a on half-
life of cytokine mRNA . B-CLL cells
were cultured for 24 h in the presence
ofTNF or TNF and IFN-a . Actino-
mycin D was added to cultures, and
mRNA was harvested at intervals for
4 handrunon a Northern blot . Ethi-
dium bromide staining shows equal
loading at all time points . Panela shows
thatTNFmRNA degradesrapidly over
this time course while1hbulinmRNA
is unaffected, panel b shows that in three
Patients (1 HCL, 2B-CLL), the half-
life is reduced still further in the pres-
ence ofIFN-a (in the examples shown
by 33-50%) .the production of autocrine growth factors by HCL and
B-CLL cells by reducing accumulation ofmRNA for a number
of cytokines, including IIr1a anda, TNF-a, and ID6. At
the same time, IFN-a increases the expression of mRNA
for the enzyme 2-5A synthetase, a ribonuclease activator. Anal-
ysis of the kinetics of cytokine mRNA production shows
that levels fall shortly afterthe rise of2-5A synthetase mRNA
(Figs. 1 and 2). The fall in cytokine mRNA may therefore
be a consequence of induction ofribonuclease activity by 2-5A
synthetase, particularly as TNF mRNA half-life is reduced
in the presence of IFN-a.
While accumulation ofmRNA for a number of cytokines
is reduced by IFN-a, mRNA levels for structural proteins
such as tubulin are not detectably affected. Differences in the
sensitivity of the mRNAs for cytokine and structural pro-
teins to IFN-a-induced ribonucleases may reflect differences
in their 3' untranslated regions. These 3' sequences regulate
message instability (19, 20) and may confer susceptibility to
IFN-a-induced ribonucleases. Preliminary observations show
that these in vitro effects of IFN-a are reproduced in vivo.
Treatment of patients with IFN-a rapidly reduces the con-
tent of TNF mRNA in B-CLL cells, whileproducing a cor-
responding increase in cellular 2-5A synthetase activity (De
Mel et al., unpublished observations).
We suggest that IFN-a exerts its therapeutic effects by
reducing endogenous growth factor production rather than
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